These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7838036)

  • 41. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
    Khera S; Mahajan D; Barbind K; Dhingra S
    Cancer Chemother Pharmacol; 2023 Apr; 91(4):331-336. PubMed ID: 36951972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.
    Lucchesi M; Guidi M; Fonte C; Farina S; Fiorini P; Favre C; de Martino M; Sardi I
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):857-64. PubMed ID: 26988222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
    Plard C; Bressolle F; Fakhoury M; Zhang D; Yacouben K; Rieutord A; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):609-20. PubMed ID: 17195068
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.
    Zhang C; Zhai S; Yang L; Wu H; Zhang J; Ke X
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):11-21. PubMed ID: 20040335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India.
    Dhingra H; Kalra M; Mahajan A
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28394. PubMed ID: 32813334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
    Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
    Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Population pharmacokinetics of high-dose methotrexate administered in 329 children with acute lymphoblastic leukemia].
    Zhang CY; Gu J; Li YZ; Lu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):106-10. PubMed ID: 18315911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.
    Rask C; Albertioni F; Bentzen SM; Schroeder H; Peterson C
    Acta Oncol; 1998; 37(3):277-84. PubMed ID: 9677100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia.
    Borsi JD; Wesenberg F; Stokland T; Moe PJ
    Eur J Cancer; 1991; 27(8):1006-9. PubMed ID: 1832883
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
    Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
    Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
    Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
    J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methotrexate plasma pharmacokinetics: importance of assay method.
    Eksborg S; Albertioni F; Rask C; Beck O; Palm C; Schroeder H; Peterson C
    Cancer Lett; 1996 Nov; 108(2):163-9. PubMed ID: 8973590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxicity following concurrent intrathecal and moderate-dose intravenous methotrexate.
    Blatt J; Howrie DL; Wollman MR; Phebus C; Mirro J
    Leukemia; 1993 Nov; 7(11):1734-7. PubMed ID: 8231243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A decrease in vitamin D levels is associated with methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
    Oosterom N; Dirks NF; Heil SG; de Jonge R; Tissing WJE; Pieters R; van den Heuvel-Eibrink MM; Heijboer AC; Pluijm SMF
    Support Care Cancer; 2019 Jan; 27(1):183-190. PubMed ID: 29922939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.